The proposed contribution of glucose variability to the development of the complications of diabetes beyond that of glycemic exposure is supported by reports that oxidative stress, the putative mediator of such complications, is greater for intermittent as opposed to sustained hyperglycemia. Variability of glycemia in ambulatory conditions defined as the deviation from steady state is a phenomenon of normal physiology. Comprehensive recording of glycemia is required for the generation of any measurement of glucose variability. To avoid distortion of variability to that of glycemic exposure, its calculation should be devoid of a time component. *Diabetes* 62:1398–1404, 2013

The salutary effect reported in the Diabetes Control and Complications Trial (DCCT) (1) and the UK Prospective Diabetes Study (2) on the development and progression of microvascular complications of diabetes has been ascribed to reduced glycemic exposure. This interpretation has been challenged (3) as overlooking the potential for additional benefit accruing from reduced glycemic variability. Its proponents have emphasized the meager ∼11% variation in retinopathy risk attributable to glycemic exposure in the DCCT (4) while minimizing the 96% treatment effect attributable to HbA1c (5). The limitations inherent to retrospective analyses notwithstanding, several have reported no effect of glucose variability in the DCCT (6–8). Oxidative stress, the putative mediator of diabetes complications (9), has been reported to be greater for intermittent as opposed to sustained hyperglycemia under experimental conditions (10) with qualified confirmation in clinical studies (11,12). The potential role for glycemic variability in the genesis of diabetes complications appears, therefore, to be an open question.

Implicit in the premise that variability is the deviation from steady state is the acknowledgment that a modest degree of variation of glycemia is characteristic of normal glucose homeostasis. Although linked glucose variability must be distinguished from glycemic exposure, glycemic variability mandates restriction to a description of glucose excursions exclusive of a time component. Glucose excursion × time = glycemic exposure. Glucose excursion/time = slope is an indicator of rate of glucose change but not its extent. Consider two identical glucose excursions differing in duration by a factor of 2: the distortion of variability varies from twofold to fourfold when time is used as a multiplier or divisor, respectively.

Differences in the unpredictability of glycemia, recognized once insulin became available in the early 1920s, found partial explanation in the characterization by Himsworth (13) in 1936 of diabetes as insulin sensitive or insulin insensitive. Variation in lability of glycemia was confirmed in subsequent studies that quantified glycemic behavior in the assessment of the effectiveness of modified insulins (14–16). In those reports and others (17) committed directly to the measurement of glycemic variability, various manipulations of intermittent blood and urine glucose determinations amounted to crude estimates of a combination of within-day (nyctohemeral) and between-day glycemic behavior. None has endured, presumably because of incomplete ascertainment of glycemia. Day-to-day glucose variability devolves primarily to a comparison of differences in mean glycemia or its surrogates and as such is phenomenologically different from nyctohemeral variability and will not be discussed here.

**MEASURES OF GLUCOSE VARIABILITY**

**M-value.** The M-value of Schlichtkrull (18,19) has proven to be a durable nyctohemeral measurement of glycemic behavior. It was the mean of the logarithmic transformation of the deviation from a reference value of six blood sugar (BS) measurements taken over a 24-h period plus an amplitude correction factor (Table 1). The latter is the difference between maximum and minimum BS values for the 24-h period divided by 20 (W/20). In the following formula, PG is plasma glucose.

\[
\text{M-value} = \left( \frac{\sum M_{\text{BS}}}{N} + \frac{W}{20} \right) \text{ where } M_{\text{BS}} = \left| \log_{120} \frac{P_{G}}{120} \right|
\]

The formula gives greater emphasis to hypoglycemia than hyperglycemia. The choice of 120 mg/dL as the reference value is somewhat puzzling since the intent of the creators of the M-value was to determine “the difference between the observed blood sugar and normal blood sugar” (18), which was 95 mg/dL in their reference group of normal patients (20). A plausible explanation is that the M-value was generated initially from data of persons with diabetes and a margin of safety was permitted. Fidelity to the original intent of the M-value warrants using a reference value consonant with basal glycemia in normal subjects, e.g., 80 for whole blood (21) and 90 for plasma measurements of glucose (22) (Table 1). When this principle is applied, comparisons among various studies can be done as long as the reference value for each study in question uses the normal basal glucose value as determined by local methodology. When 25 or more glucose values are obtained over a 24-h period, the amplitude correction factor can be eliminated (23). Unfortunately, the M-value is not an indicator solely of glucose variability but is a hybrid measure of both variability and mean glycemia.

**Mean amplitude of glycemic excursions.** The development of continuous in vivo blood glucose (BG) analysis in the 1960s eliminated the shortcomings of intermittent discrete BG sampling (24). Application of this methodology
was pursued in only a few centers worldwide and often only for descriptive purposes (25,26). In contrast, G.D. Molnar of the Mayo Clinic dedicated this tool to the furtherance of his longstanding interest in the quantification of "brittle diabetes" (17,27). Since the ultimate goal in the treatment of diabetes is the restoration of glycemia to that of persons without diabetes, the Mayo group argued that the generation of a metric of glycemic excursions should begin with an examination of the profiles of nondiabetic individuals. Furthermore, such a measure should be simple in concept and faithful to the physiological basis for the glucose swings. To do otherwise would condemn the endeavor to the fruitless task of bringing order from the chaos of the glucose profiles characteristic of type 1 diabetes and risk failure to establish biological relevance.

Because interest lay in the amplitude of glycemic swings and not in the dispersion of all the glucose data, SD was considered to be unsuitable. Because glycemic excursions in normal subjects occurred solely in response to food ingestion (Fig. 1), their recognition required a criterion exclusive to the meal-related glycemic responses. Use of an absolute value of BG such as 25 mg/dL or 50 mg/dL as a criterion for a glucose swing was abandoned because each failed to account for all of the meal-related nondiabetic glucose excursions. Upon reflection, an absolute value of BG was an ill-conceived benchmark because it failed to recognize that even among normal subjects the responses to identical food-related perturbations may result in differing glucose elevations. The criterion, which did recognize all of the meal-related glucose excursions for all of the normal subjects, was the SD of the mean BG for each 24-h period of study (288 values taken q5min from the continuous record) for each individual (Fig. 1). In contrast, 0.5 SD and 1.5 SD were less inclusive/exclusive.

The M-value has been modified from the original reference value of 120 mg/dL to 90 mg/dL to reflect normal basal glycemia when glucose is measured by a specific method on plasma. When there are >25 glucose values/24 h the amplitude correction factor W/20 can be eliminated. $^aM_{BS} = \frac{10 \log \frac{PG}{90}}{W/20}$.
Glycemic excursions of the same magnitude may qualify for one subject but not for another should the SD of the latter be larger than that of the former. The excluded excursion is not lost, however, but is incorporated into a larger one of which it is a part. Whether this is problematic is unknown. Should the subsumed excursion be of a magnitude observed for normal subjects its exclusion may be inconsequential relevant to the risk for the development of microvascular complications of diabetes.

The arithmetic mean of the glycemic excursions for the period of study (24 h, 48 h, or longer) is the value of mean amplitude of glycemic excursions (MAGE) (21).

An automated algorithm has been created for the calculation of MAGE (28). Although created for determination from continuous BG analysis, MAGE has been applied to intermittent (7- and 22-point sampling/24 h) measurements (6,29) as well as continuous interstitial glucose monitoring (30).

**SD.** SD is a commonly reported expression of glucose variability. Its ease of calculation and possible concern that its absence would impugn authors’ commitment to a comprehensive assessment of variability drives its inclusion in virtually all articles on this topic. SD is not a fallback measure by any means; it does have vigorous support (31). Unfortunately its utility is hampered by the lack of Gaussianness of glucose profile data (Fig. 3) and the potential for widely different glycemic curves having the identical numerical value of SD (32).

**J-index.** The J-index perpetuates the inclusion of SD into the measurement of glycemic variability. Originally derived from intermittent BG determinations, it has been adapted to continuous monitoring data. Its proponent recommends it as a measure of both the mean level and variability of glycemia (33). This parameter has not been widely used. In the following formula, MBG is mean BG.

![FIG. 2. Continuous BG analysis for 48 h in a patient with type 1 diabetes. The qualifying excursions are shown as pairs of solid and stippled yellow beginning with the leftmost deflection, 333 to 208 mg/dL. The inflection component of that excursion is 208 to 432 mg/dL, which incorporates an intermediary excursion. The latter fails to qualify as an excursion on its own because one limb (322 to 287 mg/dL) fails to exceed 1 SD for that 24-h period. Note the small difference in SD from day 1 to day 2. Whether MAGE is calculated from the descending (184 mg/dL) or ascending (171 mg/dL) limbs, the values are similar. M, meal; Sn, snack.](image)

![FIG. 3. Frequency distribution of the 576 glucose values/48 h from Fig. 1 plotted per 24-h period showing a lack of normal distribution.](image)
Mean absolute difference, mean absolute glucose, and continuous overall net glycemic action $n$. Three parameters based on the analyses of sequential BG values have been proposed as measures of glycemic variability. The mean absolute difference (MAD) of consecutive BG values was derived from self-monitored BG data performed five times per 24 h (34). The authors have acknowledged that MAD has no advantage over SD as an estimate of glycemic variability.

Mean absolute glucose (MAG) is the summed differences between sequential 7-point self-measured BG profiles per 24 h divided by the time in hours between the first and last BG measurement (35). A limitation to MAG is that two excursions of identical extent but of different duration have different values.

Continuous overall net glycemic action (CONGA) $n$, was conceived for continuous interstitial glucose monitoring. Analysis requires a complete tracing, i.e., 288 values per 24 h. For each glucose datum after the first $n$ hours of observations, the difference between the current glucose and the glucose $n$ hours previous is determined. $n$ can vary from 1 to 8 h. For instance, for $n = 1$ and 24-h period of monitoring beginning at 0800, the calculations would begin as follows: BG at 0900 minus BG at 0800; BG at 0905 minus BG at 0805; BG at 0910 minus BG at 0810 and so on until BG 0800 (the next day) minus BG at 0700 (Fig. 4). The period of analysis is 24 h minus $n$. CONGA is expressed as the SD of the differences despite their lack of normal distribution (Fig. 4) (36).

For none of these parameters—MAD, MAG and CONGA $n$—has a rationale been promulgated to support its use. Since each was based on examinations of tracings from patients with diabetes rather than normal subjects, it is difficult to assign any biological relevance to them. Reliance solely on mathematical manipulations to the exclusion of relevance is analogous to the feckless statistician who drowned wading across a river whose average depth he calculated to be 4 feet: failure to appreciate the relevance of the variation in water depth from shore to shore was his undoing.

Inclusion of all data points fails to discriminate glycemia directly related to excursions from that which might be considered as noise. Furthermore, it is difficult to identify a biorhythm with periodicities of 1, 2, 3, or more hours implicit in the generation of CONGA $n$.

**Postprandial glycemia.** For postprandial hyperglycemia to play a role in the development of diabetes complications, its influence must exceed its contribution to mean glycemia. Otherwise the effect of improved mean glycemia is amenable to study with techniques less arduous than the task of controlling postprandial hyperglycemia (37). Implicit in the putative special role for postprandial glucose is the assumption of unique properties associated with the meal-related glucose excursion not attendant upon hypoglycemia of a similar degree in the interprandial state (10,11). A clinical trial designed to assess the effect of postprandial glucose on the development of diabetes complications must ensure no difference in HbA1c or mean glycemia while generating a difference in postprandial glycemia. To achieve these goals, the interprandial glucose would of necessity have to increase, thereby resulting in reduced glucose excursions (38). When measured in this context postprandial glucose therefore takes on the mantle of a surrogate for glycemic variability.

Assessment of postprandial glycemia poses not just a difficult but a virtually impossible task when limited to one after-meal determination: a static measurement in

\[
J = 0.001(\text{MBG} + \text{SD})^2 \text{ for glucose measured in mg/dL}
\]

\[
J = 0.324(\text{MBG} + \text{SD})^2 \text{ for glucose measured in mmol/L}
\]
a dynamic situation. In persons without diabetes, glucose responses to food ingestion are influenced by the size, composition, and time of day of the meal (39,40). The responses in patients with diabetes are more variable (41). Even in the situation of complete ascertainment from continuous glucose monitoring, reliance on peak postprandial glucose as a measure of variability is fraught with potential error because it represents only the north end of the meal-related excursion; without the south end there is no actual excursion. Without documentation of the starting point of an excursion its size cannot be known.

**Low BG index, high BG index, and glycemic risk assessment diabetes equation.** Two quantifications of risk for hypoglycemia and hyperglycemia have been reported under the rubric of glucose variability (42,43). High BG index (HGBI) and low BG index (LBGI) are generated from a correction of the skewness of glycemia (narrow hypoglycemic vs. broad hyperglycemic range) through a symmetrization process around zero (equivalent to glucose 112.5 mg/dL) by expanding the hypoglycemic range and reducing the hyperglycemic range (42).

\[
LBGI = \frac{1}{n} \sum_{i=1}^{n} r(X_i)
\]

\[
HGBI = \frac{1}{n} \sum_{i=1}^{n} rh(X_i)
\]

f(BG) = 1.509 × \left( \frac{\ln(BG)}{10^{0.84} - 5.381} \right) \quad \text{for BG in mg/dL}
\]

f(BG) = 1.509 × \left( \frac{\ln(18 \times BG)}{10^{0.84} - 5.381} \right) \quad \text{for BG in mmol/L}

r(BG) = 10 × f(BG)^2

r(BG) = r(BG) \quad \text{if } f(BG) < 0 \text{ and 0 otherwise}

rh(BG) = r(BG) \quad \text{if } f(BG) > 0 \text{ and 0 otherwise}

The rationale for this maneuver is not stated nor is it readily inferred since risks associated with hypoglycemia are different from those associated with hyperglycemia in type, timing, and predictability, and they have no interaction. Larger values of LBGI and HGBI indicate higher risk for hypoglycemia and hyperglycemia, respectively. Although originally developed from self-monitored BG data, these parameters have been adapted to continuous interstitial glucose monitoring (44). Correlations between LBGI and subsequent hypoglycemia and between HGBI and HbA1c have been reported.

The glycemic risk assessment diabetes equation (GRADE) score was created to summarize the degree of risk associated with a glucose profile (43). Qualitative risk scoring for a wide range of glucose levels inclusive of marked hypoglycemia and hyperglycemia was generated by a committee of diabetes practitioners. The nature of the risk was not specified. In the determination of GRADE, glucose values are transformed to yield a continuous curvilinear response with a nadir of 90 mg/dL and high adverse weighting to hyperglycemia and hypoglycemia.

mmol/L GRADE value = 425x \left[ \log(\log(X)) + 0.16 \right]^2

mg/dL GRADE value = 425x \left[ \log(\log(X \times 18)) + 0.16 \right]^2

where X = blood glucose

Since a high GRADE score may be generated from either hyperglycemia or hypoglycemia, the range of glucose contributing to the score is reported as percentages: <70 mg/dL (hypoglycemia), 70–140 mg/dL (euglycemia), and >140 mg/dL (hyperglycemia).

Neither LBGI/HGBI nor GRADE measures glucose fluctuations directly. Since both manipulations use all of the available glucose data, the highly derivatized results appear to be an expression of quasi mean glycemia (LBGI/HGBI) or a frequency distribution (GRADE). Unfortunately, the term “risk” may not serve these parameters well, especially in the context of predicting future events. An undesirable value of LBGI, HGBI, or GRADE should lead to an immediate change in therapy for the purpose of mitigating future adverse events rather than act as predictors in the face of persistent flawed treatment.

**1,5-anhydroglucitol.** This substance has been proposed as a surrogate marker for glycemic excursions (45). Once circulating glucose levels exceed the renal threshold for glucosuria plasma, levels of 1,5-anhydroglucitol (all because its renal reabsorption is competitively inhibited by glucose. Distinction between chronic and intermittent hyperglycemia, both of which are characterized by low concentrations of 1,5-anhydroglucitol, is governed by the HbA1c level, which when normal or near-so suggests intermittent forays of glycemia into the hyperglycemic range, i.e., large glycemic excursions. There are several limitations of 1,5-anhydroglucitol as a measure of glycemic variability. It does not measure glucose fluctuations directly and therefore cannot determine their size and frequency or those occurring below a BG ~180 mg/dL and is not useful when the HbA1c level is elevated.

**GLUCOSE VARIABILITY AND THE COMPLICATIONS OF DIABETES**

There have been no randomized clinical trials directed at this question despite inferences from secondary analyses (6–8). Although the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) trial, which compared prandial to basal glucose control, was (38) not specifically designed to evaluate glycemic variability, inferences can be drawn from the narrower range of glucose values in the prandial wing. A retrospective analysis concluded that improved glycemic variability (lower MAG with no differences in SD or MAGE) in the prandial versus basal treatment groups had no effect on cardiovascular outcomes (46). This interpretation has been disputed partly on the basis of the exclusive reliance on MAG, an alleged unvalidated measure of variability to the exclusion of other established metrics (47). In a cross-sectional study of type 1 and type 2 diabetic patients an association was found between cardiovascular risk factors and measures of average glycemia (mean BG and HbA1c) but not with measures of glycemic variability (MAGE, CONGA 4, and postprandial glucose increment) (48). In a randomized trial in type 2 diabetes not specifically designed to address the effect of glycemic variability, lower postprandial and higher fasting glycemia led to a regression in carotid intima thickness despite no change in HbA1c (49).

**FUTURE**

There should be no doubt that pharmacological advances directed to the ultimate goal of physiological insulin replacement will continue with the eventual development of faster-acting/shorter-duration insulins to the point where
the postprandial glycemic curve will be bent to conform to that of nondiabetic subjects. In that utopian situation, the currently available measures of glycemic variability can be retired. In their place, specific metrics that characterize the primary features of the meal-related excursion such as glucose rise to peak, time to peak, and timeliness of recovery to baseline glycemia would be appropriate (Fig. 5) (50).

CONCLUSIONS
Analogous to the vital role played by HbA1c in testing the long-term complications in insulin-dependent diabetes mellitus (51), the variability of postprandial glycemia during ambulatory fed conditions it has not been adapted to the free-living state. Although not constrained by that limitation, continuous interstitial glucose monitoring is hampered by variable and unpredictable inaccuracies (51). The task therefore, of assessing a role for glycemic variability in the development of diabetes complications is fraught with difficulty. The question may ultimately prove to be moot should elimination of the complications of diabetes ensue from the bending of the prandial glycemic curve to that of nondiabetic subjects.

ACKNOWLEDGMENTS
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and the risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352:837–853
3. Hirsch IB, Brownlee M. Should minimal BG variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178–181
4. Trence DL, Hirsch IB. Motherhood, apple pie, hemoglobin A1C, and the DCCT. Endocr Pract 2012;18:78–84
5. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—revisited. Diabetes 2008;57:995–1001
6. Service FJ, O’Brien PC. The relation of glycemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 2001;44:1215–1220
7. Kilpatrick ES, Rigby AS, Atkins SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29:1486–1490
8. Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoeckstra JB, Devery JH. Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 2009;52:2229–2232
9. Brownlee M. Biochemistry and molecular biology of diabetic complications. Nature 2001;414:813–820
10. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008;57:1348–1354
11. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687
12. Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010;53:562–571
13. Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936;2:127–130
14. Izzo JL, Crump SL, Kunz W. A clinical comparison of modified insulins. J Clin Invest 1950;29:1514–1527
15. Hallas-Moller K, Jersild M, Petersen K, Schlichtkrull J. The lente insulins, insulin-zinc suspensions. Dan Med Bull 1954;1:132
16. Gurling KJ, Robertson JA, Whittaker H, Oakley W, Lawrence RD. Treatment of diabetes mellitus with insulin zinc suspensions: a clinical study based on 479 cases. BMJ 1955;1:71–74
17. Molnar GD, Gastineau CF, Rosevear JW, Moxness KE. Quantitative aspects of faible diabetes. Diabetes1965;4:279–88
18. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar concentration of human subjects during continuous sampling. Acta Med Scand 1965;177:95–102
19. Schlichtkrull J, Funder J, Munck O. Clinical Evaluation of a New Insulin Preparation. 4e Congres de la Federation Internationale du Diabete. Demole M, Ed. Geneva, Editions Medecine et Hygiene, 1961, p. 303–305
20. Trimble H, Maddock S. The fluctuations of the capillary blood sugar in normal young men during a twenty-four hour period (including a discussion of the effect of sleep and of mild exercise). J Biol Chem 1929;811:505–611
21. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644–655
22. Service FJ, Nelson RL. Characteristics of glycemic stability. Diabetes Care 1980;3:58–62
23. Mirouze J, et al. Coefficient d’efficacite insulique, coefficient M de Schlichtkrull corrigé et simplifié par la technique de l’enregistrement glycémique continu. Diabete 1963;11:267–273 [in French]
24. Weller C, Linder M, Macaulay A, Ferrari A, Kessler G. Continuous in vivo monitoring of diabetes mellitus with insulin zinc suspensions. Acta Med Scand 1965;177:95–102
25. Mirouze J, Jaffiol C, Sany C. Enregistrement glycémique nchtéméral continu dans le diaabte instable. Rev Fr Endocrinol Clin 1962;3:337–353
26. Burns TW, Bregant R, Vanpeenen HH, Hood TE. Observations on blood glucose concentration of human subjects during continuous sampling. Diabetes 1965;14:186–193
27. Molnar GD. Observations on the etiology and therapy of “brittle” diabetes. Can Med Assoc J 1964;90:553–565
28. Baghurst P. Calculating the mean amplitude of glycemic excursion from continuous glucose monitoring data: an automated algorithm. Diabetes Technol Ther 2011;13:296–302
29. Service FJ, O’Brien PC, Rizza RA. Measurements of glucose control. Diabetes Care 1987;10:225–237
30. Cameron FJ, Donath SM, Baghurst PA. Measuring glycemic variation. Curr Diabetes Rev 2010;6:17–26
31. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009; 11:551–565
32. Siegelaar SE, Hollemann F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010;31:171–182
33. Wójcicki JM. "J"-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res 1995;27:41–42
34. Moberg E, Kollind M, Lins PE, Adamson U. Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1993;53:507–514
35. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838–842
36. McDonnell CM, Donath SM, Vidmar SI, Werther GA, Cameron FJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther 2005;7:253–263
37. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090–2095
38. Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381–386
39. Service FJ, Hall LD, Westland RE, et al. Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in normal subjects. Diabetologia 1983;25:316–321
40. Jenkins DJ, Wolever TM, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981;34:362–366
41. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001;24:775–778
42. Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care 1997;20:1655–1658
43. Hill NR, Hindmarsh PC, Stevens RJ, Stratton IM, Levy JC, Matthews DR. A method for assessing quality of control from glucose profiles. Diabet Med 2007;24:753–758
44. Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther 2005;7:849–862
45. Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 2008;8:9–19
46. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011;34:855–857
47. Monnier L, Colette C. Glycemic variability: can we bridge the divide between controversies? Diabetes Care 2011;34:1058–1059
48. Borg R, Kuenen JC, Carstensen B, et al.; ADAG Study Group. HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011;54:69–72
49. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214–219
50. Service FJ. Normalization of plasma glucose of unstable diabetes: studies under ambulatory, fed conditions with pumped intravenous insulin. J Lab Clin Med 1978;91:480–489
51. Facchinetti A, Sparacino G, Cobelli C. Modelling the error of continuous glucose monitoring sensor data: critical aspects discussed through simulation studies. J Diabetes Sci Technol 2010;4:4–14